Quantity of eligible clients: CDEC discussed the uncertainty in the number of individuals with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some sufferers who're labeled as obtaining mild or moderate condition might have a extreme bleeding phenotype, which https://trevormroav.weblogco.com/35921760/the-best-side-of-hemgenix